Anti-tumor activity of some 1,3,4-thiadiazoles and 1,2,4-triazine derivatives against Ehrlichs Ascites Carcinoma

Abstract

Recently, identifying new chemo-preventive agents to replace the current chemotherapies consider one of the most important approaches which could be crucial for cancer treatment. The present study was conducted to evaluate the anti-tumor activity of some newly synthesized heterocyclic 1,3,4-thiadiazole and 1,2,4-triazine derivatives. Different groups of mice were inoculated with Ehrlichs Ascites Carcinoma cells (EAC) intra-peritoneal (i.p.) (2×l06 cells mouse-1). After one day of inculcation, mice were treated either with cisplatin (reference drug) or with twenty five different new derivatives of 1,3,4-thiadiazoles or 1,2,4-triazines. The anti-tumor activity of these derivatives against EAC-bearing mice were monitored through the changes in the total body weight, total ascetic volume, the number of live and dead tumor cells, median survival time (MST) and some biochemical parameters. The results showed that only five compounds of 1,3,4-thiadiazoles significantly inhibited the tumor progression after 14 days of the treatment. Interestingly, two of these compounds increased the life span of the tumored mice by 34 and 40% when compared with the untreated group. In contrast, all 1,2,4-triazine derivatives didn't show any potential anti-tumor activity against EAC-model. In conclusion, screening of 1,3,4-thiadiazole derivatives showed a potential activity against EAC while, 1,2,4-triazine derivatives didn't show any marked anti-tumor activity. © 2011 Academic Journals Inc.